pp: A newly identified CD45-associated protein
    4.
    发明授权
    pp: A newly identified CD45-associated protein 失效
    pp32:新鉴定的CD45相关蛋白

    公开(公告)号:US5510461A

    公开(公告)日:1996-04-23

    申请号:US197793

    申请日:1994-02-14

    CPC分类号: C07K14/47 A61K38/00

    摘要: This invention relates to a newly identified protein useful for treating diseases of the immune system, methods for obtaining said protein, isolated nucleic acids encoding said protein, and methods for obtaining inhibitors of said protein. The protein of this invention is characterized by an apparent molecular weight of about 32 kD, an isoelectric point of about 4.0-4.5 and coprecipitation with CD45. The protein may also be used in in vitro or in vivo assays to identify inhibitors of T cell activation.

    摘要翻译: 本发明涉及可用于治疗免疫系统疾病的新鉴定的蛋白质,获得所述蛋白质的方法,编码所述蛋白质的分离的核酸,以及获得所述蛋白质抑制剂的方法。 本发明的蛋白质的特征在于表观分子量为约32kD,等电点为约4.0-4.5,并与CD45共沉淀。 该蛋白质也可用于体外或体内测定以鉴定T细胞活化的抑制剂。

    ASSAY AND METHOD FOR THE IDENTIFICATION OF INDIVIDUAL RESPONSIVENESS TO IMMUNOGLOBULIN THERAPY
    10.
    发明申请
    ASSAY AND METHOD FOR THE IDENTIFICATION OF INDIVIDUAL RESPONSIVENESS TO IMMUNOGLOBULIN THERAPY 审中-公开
    用于识别免疫球蛋白治疗的个体反应的测定和方法

    公开(公告)号:US20150211064A1

    公开(公告)日:2015-07-30

    申请号:US14114276

    申请日:2012-06-06

    IPC分类号: C12Q1/68

    摘要: A method for determining the likelihood of response of an individual, suffering from a disease, towards immunoglobulin therapy has the steps of providing a sample containing B- and T-lymphocytes, natural killer cells, invariant T-cells and monocytes of the individual; genotyping of at least one of the polynucleotides of an ADAMTS9-Intron; a KLHDC8A-Intron or of a flanking region of the CD14 gene, and awarding the value of 1 for the homozygous Single Nucleotide Polymorphism combinations, which suggests that the blood sample stems from a person which will not respond to immunoglobulin treatment, while awarding the value of 0 for SNP not meeting that criteria, which suggests that the blood sample stems from a person which will respond to immunoglobulin treatment.

    摘要翻译: 确定患有疾病的个体对免疫球蛋白治疗的反应可能性的方法具有以下步骤:提供含有个体的B和T淋巴细胞,天然杀伤细胞,不变T细胞和单核细胞的样品; 至少一种ADAMTS9-内含子的多核苷酸的基因分型; KLHDC8A-内含子或CD14基因的侧翼区域,并且为纯合的单核苷酸多态性组合赋予1值,这表明血液样品源于不对免疫球蛋白治疗反应的人,同时赋予该值 为0的SNP不符合该标准,这表明血液样本来源于将对免疫球蛋白治疗作出反应的人。